Are biosimilars for Humira on the market yet?
Yes. The FDA has approved multiple biosimilars for Humira (adalimumab), and several are already available to patients in the US. These include Amjevita (Amgen), Cyltezo (Boehringer Ingelheim), Hyrimoz (Sandoz), Hadlima (Samsung Bioepis), Abrilada (Pfizer), Hulio (Mylan), and Idacio (Fresenius Kabi).
How much do Humira biosimilars cost compared with the original?
Prices vary by payer and pharmacy benefit manager, but most biosimilars launched with list prices 5–30 % lower than Humira. After rebates and discounts, net prices for many plans are reported to be 80–85 % below Humira’s peak price. Actual patient copays depend on insurance coverage and whether the product is placed on formulary.
When did Humira’s main patent protection end?
AbbVie’s key composition-of-matter patent expired in 2023. Earlier settlements with biosimilar makers allowed limited launches in 2023, followed by broader availability starting in 2024. A few additional patents remain active, but they have not blocked the current wave of biosimilar launches.
Which biosimilars are interchangeable with Humira?
Only Cyltezo currently carries the FDA’s “interchangeable” designation, meaning pharmacists can substitute it for Humira without a new prescription in some states. The other approved biosimilars are highly similar but lack that formal interchangeability status.
Are there any differences in safety or effectiveness?
All approved biosimilars met FDA standards showing no clinically meaningful differences from Humira in structure, purity, potency, and clinical performance. Real-world data collected since 2023 have not revealed new safety signals beyond those already known for adalimumab products.
How do doctors and patients decide which version to use?
Insurer formulary placement, copay assistance programs, and physician familiarity drive most choices. Some practices have switched stable patients to a biosimilar to reduce overall treatment costs, while others continue Humira when patients have responded well and coverage remains favorable.
Who makes the leading biosimilars and where can I find current patent status?
Major developers include Amgen, Boehringer Ingelheim, Sandoz, Samsung Bioepis, Pfizer, and Fresenius Kabi. Updated patent and exclusivity data for both the originator and biosimilars are tracked on DrugPatentWatch.com.